Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203372 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00203372 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 6 participants.
The verdict
NCT00203372, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
Interventions
- DRUG Bevacizumab 7.5 and TAC
- DRUG Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
- DRUG Bevacizumab 15 and TAC
- DRUG Placebo 15 and TAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203372
The ClinicalTrials.gov registry entry for NCT00203372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab 7.5 and TAC is the first listed.
NCT00203372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203372 about?
NCT00203372 is a clinical study titled "Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)". The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
What is the current status of trial NCT00203372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2005-05.
What interventions are being tested in trial NCT00203372?
The interventions under investigation include: Bevacizumab 7.5 and TAC (DRUG), Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (DRUG), Bevacizumab 15 and TAC (DRUG), Placebo 15 and TAC (DRUG).
Who is sponsoring clinical trial NCT00203372?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.